TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20677478

Group type: EXPERIMENTAL
Intervention: Attendance at specialized prenatal clinics for Native American women (both rural and urban locations)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control group (not attending specialized prenatal clinics)
Number of subjects: 154
Study: 18004930

Group type: EXPERIMENTAL
Intervention: En masse retraction
Number of subjects: 30

Group type: COMPARATOR
Intervention: Two-step retraction
Number of subjects: 30
Study: 15958334

Group type: EXPERIMENTAL
Intervention: Cefazolin (single dose) prior to TACE
Number of subjects: 60

Group type: COMPARATOR
Intervention: No prophylactic antibiotics (NONE group)
Number of subjects: 60
Study: 11990744

Group type: EXPERIMENTAL
Intervention: High volume of exercise with carbohydrate-protein supplementation
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Moderate volume of exercise with carbohydrate-protein supplementation
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Low volume of exercise with carbohydrate-protein supplementation
Number of subjects: 7

Group type: COMPARATOR
Intervention: High volume of exercise with placebo
Number of subjects: 7

Group type: COMPARATOR
Intervention: Moderate volume of exercise with placebo
Number of subjects: 7

Group type: COMPARATOR
Intervention: Low volume of exercise with placebo
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Carbohydrate-protein supplementation
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 9667603

Group type: EXPERIMENTAL
Intervention: ApoE epsilon4 allele frequency in FTD patients
Number of subjects: 33

Group type: COMPARATOR
Intervention: ApoE epsilon4 allele frequency in early-onset Alzheimer's disease (EOAD) patients
Number of subjects: 33

Group type: COMPARATOR
Intervention: ApoE epsilon4 allele frequency in late-onset Alzheimer's disease (LOAD) patients
Number of subjects: 33

Group type: COMPARATOR
Intervention: ApoE epsilon4 allele frequency in non-demented elderly controls
Number of subjects: 33
Study: 8208596

Group type: EXPERIMENTAL
Intervention: Exosurf Neonatal (5 mL/kg)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Survanta (4 mL/kg)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (no surfactant administration)
Number of subjects: 34
Study: 2645569

Group type: EXPERIMENTAL
Intervention: Taurine supplementation (45 mg/L)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control (less than 5 mg/L taurine)
Number of subjects: 37
Study: 28742612

Group type: EXPERIMENTAL
Intervention: Short Sleep (SS; 6.5 hours/night in bed)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healthy Sleep Opportunity (HS; 9.5 hours/night in bed)
Number of subjects: 24
Study: 26824933

Group type: EXPERIMENTAL
Intervention: FP 250 μg MDI with Mini Spacer
Number of subjects: 0

Group type: COMPARATOR
Intervention: FP 250 μg MDI with Aerochamber
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SFC 25/250 μg with Mini Spacer
Number of subjects: 0

Group type: COMPARATOR
Intervention: SFC 25/250 μg with Aerochamber
Number of subjects: 0
Study: 25896737

Group type: EXPERIMENTAL
Intervention: Organizational Process Improvement Intervention (OPII)
Number of subjects: 1509

Group type: COMPARATOR
Intervention: Delayed-Start condition
Number of subjects: 1509
Study: 24046993

Group type: EXPERIMENTAL
Intervention: Ketofol (1-1.5 mg/kg propofol with 0.25 mg/kg ketamine)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Propofol (1-1.5 mg/kg)
Number of subjects: 40
Study: 20071105

Group type: EXPERIMENTAL
Intervention: Varenicline treatment
Number of subjects: 626
Study: 18936702

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (target blood glucose 4.4‐6.1 mmol/L or 80‐110 mg/dL)
Number of subjects: 523

Group type: COMPARATOR
Intervention: Conventional insulin therapy (target blood glucose 10‐11.1 mmol/L or 180‐200 mg/dL)
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 523

Group type: COMPARATOR
Intervention: Conventional insulin therapy
Number of subjects: 523
Study: 17201701

Group type: EXPERIMENTAL
Intervention: Discontinuation of major antiepileptic drugs (AEDs)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Continuation of major antiepileptic drugs (AEDs)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Withdrawal of carbamazepine (CBZ)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Withdrawal of valproate (VPA)
Number of subjects: 150
Study: 14998083

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanic acid (2.2 g)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Cefazolin (2 g)
Number of subjects: 360
Study: 11889279

Group type: EXPERIMENTAL
Intervention: Enhanced intervention (support groups and one-on-one contacts with peer advocates)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard group
Number of subjects: 0
Study: 9459032

Group type: EXPERIMENTAL
Intervention: Hypertext tutorial
Number of subjects: 2

Group type: COMPARATOR
Intervention: Conventional lecture
Number of subjects: 2
Study: 7933040

Group type: EXPERIMENTAL
Intervention: Ultrasonographic evaluation of esophagogastric junction and alimentary tract diameter in patients with sliding hiatal hernia.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ultrasonographic signs (non-visualization of the esophagogastric junction and diameter greater than 16 mm) evaluated in a prospective study of 38 patients.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal controls (18 patients)
Number of subjects: 30
Study: 2834746

Group type: EXPERIMENTAL
Intervention: 200 mg itraconazole for 1 day
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 200 mg itraconazole for 2 days
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 200 mg itraconazole for 3 days
Number of subjects: 59
Study: 31217143

Group type: EXPERIMENTAL
Intervention: Updated logistic clinical SYNTAX score
Number of subjects: 4006
Study: 28495681

Group type: EXPERIMENTAL
Intervention: Single RDTs for HIV and syphilis
Number of subjects: 2214

Group type: EXPERIMENTAL
Intervention: Dual RDTs for HIV and syphilis
Number of subjects: 2214
Study: 25475927

Group type: EXPERIMENTAL
Intervention: Rational Emotive Behavior Therapy (REBT)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 34
Study: 23298603

Group type: EXPERIMENTAL
Intervention: CYP2C9 mutant individuals (MT group; CYP2C9*2 and *3)
Number of subjects: 100

Group type: COMPARATOR
Intervention: CYP2C9 wild-type individuals (WT group; CYP2C9*1)
Number of subjects: 100
Study: 20839290

Group type: EXPERIMENTAL
Intervention: Denosumab (60 mg subcutaneous injections every 6 months for 3 years)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo (subcutaneous injections every 6 months for 3 years)
Number of subjects: 160
Study: 17443126

Group type: EXPERIMENTAL
Intervention: 14 mg transdermal nicotine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 17136583

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type B (BT‐B) intravesical injections (5000 MU, 1 ml, diluted to 20 mls with normal saline, injected in 10 different sites into the detrusor)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 12616259

Group type: EXPERIMENTAL
Intervention: MNT protocol care (MNT‐PC)
Number of subjects: 394

Group type: COMPARATOR
Intervention: Usual nutrition care (UC)
Number of subjects: 394
Study: 10675165

Group type: EXPERIMENTAL
Intervention: Influenza vaccination of health-care workers
Number of subjects: 1437

Group type: COMPARATOR
Intervention: No influenza vaccination of health-care workers
Number of subjects: 1437
Study: 9091670

Group type: EXPERIMENTAL
Intervention: Monetary incentive and peer-support group
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Peer-support group only
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Monetary incentive only
Number of subjects: 286

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 286
Study: 29600688

Group type: EXPERIMENTAL
Intervention: Add-on robot-assisted gait training using the Lokomat
Number of subjects: 74

Group type: COMPARATOR
Intervention: Add-on conventional overground gait training
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Add-on robot-assisted gait training
Number of subjects: 74
Study: 26211411

Group type: EXPERIMENTAL
Intervention: Double volume exchange transfusion (DVET)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Standard therapy (ST)
Number of subjects: 83
Study: 24424070

Group type: EXPERIMENTAL
Intervention: Erythropoietin (n = 339)
Number of subjects: 683

Group type: COMPARATOR
Intervention: No erythropoietin (n = 344)
Number of subjects: 683

Group type: EXPERIMENTAL
Intervention: Erythropoietin with autologous reinfusion (n = 214)
Number of subjects: 683

Group type: COMPARATOR
Intervention: No erythropoietin with autologous reinfusion (n = 206)
Number of subjects: 683

Group type: EXPERIMENTAL
Intervention: Erythropoietin
Number of subjects: 683

Group type: EXPERIMENTAL
Intervention: Autologous blood reinfusion
Number of subjects: 683
Study: 22703892

Group type: EXPERIMENTAL
Intervention: Oxycodone 10mg / Morphine 20mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxycodone 15mg / Morphine 30mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxycodone 20mg / Morphine 40mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Morphine 40mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxycodone (all doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Morphine 20mg and 30mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Morphine 40mg and Oxycodone (all doses)
Number of subjects: 0
Study: 19199542

Group type: EXPERIMENTAL
Intervention: Amodiaquine plus sulfadoxine‐pyrimethamine
Number of subjects: 129
Study: 16961805

Group type: EXPERIMENTAL
Intervention: Lansoprazole group: 7-day course of lansoprazole 30 mg, amoxicillin 750 mg, and metronidazole 250 mg, b.i.d.
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Famotidine group: 7-day course of famotidine 40 mg, amoxicillin 750 mg, and metronidazole 250 mg, b.i.d.
Number of subjects: 61
Study: 15285122

Group type: EXPERIMENTAL
Intervention: Feature-matching similarity measure model
Number of subjects: 0

Group type: COMPARATOR
Intervention: ALCOVE model
Number of subjects: 0
Study: 11600165

Group type: EXPERIMENTAL
Intervention: Quality Improvement interventions for depression care; specific interventions not detailed.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable; control group not specified.
Number of subjects: 0
Study: 9424603

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cholesterol-lowering medication
Number of subjects: 0
Study: 7963709

Group type: EXPERIMENTAL
Intervention: Zidovudine (200 mg every 4 h)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermittent dideoxycytidine (ddC) (0.03 mg/kg every 4 h)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zidovudine and dideoxycytidine given in alternating weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intermittent zidovudine
Number of subjects: 0
Study: 3307888

Group type: EXPERIMENTAL
Intervention: Grenz rays in a total dose of 900 rad (9 Gy) given in three equal doses at 21‐day intervals
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo therapy given in a similar treatment schedule
Number of subjects: 30
Study: 31772064

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC) therapy (60 L/min) for 15 min
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional oxygen (O2) therapy for 15 min
Number of subjects: 18
Study: 28910768

Group type: EXPERIMENTAL
Intervention: Proposed image synthesis algorithm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evaluation framework for generation performance
Number of subjects: 0
Study: 28817828

Group type: EXPERIMENTAL
Intervention: Treadmill training augmented by VR (TT+VR)
Number of subjects: 281

Group type: COMPARATOR
Intervention: Treadmill training alone (TT)
Number of subjects: 281
Study: 26654101

Group type: EXPERIMENTAL
Intervention: Primaquine (PQ) with Artesunate (AS)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Primaquine (PQ) with Artesunate-Pyronaridine (AS-PYR)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Primaquine (PQ) with Dihydroartemisinin-Piperaquine (DHA-PP)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Artesunate (AS) followed by Primaquine (PQ)
Number of subjects: 180
Study: 22701039

Group type: EXPERIMENTAL
Intervention: Individual work support (up to eight individually targeted vocational sessions in conjunction with group rehabilitation for low back pain)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Group rehabilitation (control group)
Number of subjects: 51
Study: 19762159

Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 14

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 14
Study: 18419825

Group type: EXPERIMENTAL
Intervention: 5 ml/kg normal saline (Ns group, n = 32)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: 5 ml/kg 3.5% sodium chloride (Hs group, n = 30)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: 5 ml/kg 5% sodium bicarbonate (Sb group, n = 32)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (Ns and Hs)
Number of subjects: 94
Study: 16768639

Group type: EXPERIMENTAL
Intervention: Risperidone (1.5 mg/day)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Quetiapine (200 mg/day)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Olanzapine (10 mg/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 50
Study: 14984503

Group type: EXPERIMENTAL
Intervention: IV anti-D
Number of subjects: 6

Group type: COMPARATOR
Intervention: IV immunoglobulin (IVIG)
Number of subjects: 6
Study: 11053917

Group type: EXPERIMENTAL
Intervention: Calcitriol 3 microg/g ointment (twice daily)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Dithranol cream (0.25-2%, once daily for 30 min)
Number of subjects: 114
Study: 9057430

Group type: EXPERIMENTAL
Intervention: 3-day treatment with bismuth, metronidazole, and tetracycline
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 5-day treatment with bismuth, metronidazole, and tetracycline
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 7-day treatment with bismuth, metronidazole, and tetracycline
Number of subjects: 30
Study: 8161424

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus radiotherapy
Number of subjects: 143

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 143
Study: 2868657

Group type: EXPERIMENTAL
Intervention: Drug-treated group (Hydrochlorothiazide, propranolol, methyldopa)
Number of subjects: 785

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 785

Group type: EXPERIMENTAL
Intervention: Prazosin (short-term trial)
Number of subjects: 785
Study: 30149775

Group type: EXPERIMENTAL
Intervention: Copper impregnated compression stockings
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard compression stockings (control)
Number of subjects: 16
Study: 28740352

Group type: EXPERIMENTAL
Intervention: Low FODMAP diet
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Re-challenging foods after low FODMAP diet
Number of subjects: 50
Study: 25442396

Group type: EXPERIMENTAL
Intervention: Alcohol-based impregnated wipes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Quaternary ammonium-based impregnated wipes
Number of subjects: 0
Study: 23849341

Group type: EXPERIMENTAL
Intervention: Anidulafungin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluconazole
Number of subjects: 0
Study: 21718474

Group type: EXPERIMENTAL
Intervention: 1 g methylprednisolone for three consecutive days
Number of subjects: 266

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 266
Study: 18635341

Group type: EXPERIMENTAL
Intervention: Linezolid 600mg intravenously every 12h
Number of subjects: 142

Group type: COMPARATOR
Intervention: Vancomycin 1g intravenously every 12h (for patients aged < or =60 years) or 0.75g (for patients aged >60 years)
Number of subjects: 142
Study: 16507515

Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 18

Group type: COMPARATOR
Intervention: Water
Number of subjects: 18
Study: 15452309

Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11506100

Group type: EXPERIMENTAL
Intervention: 0.075 mg/kg cisatracurium
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg cisatracurium
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 0.30 mg/kg cisatracurium
Number of subjects: 48
Study: 9402568

Group type: EXPERIMENTAL
Intervention: Visual feedback group
Number of subjects: 20

Group type: COMPARATOR
Intervention: No visual feedback group
Number of subjects: 20
Study: 8291370

Group type: EXPERIMENTAL
Intervention: High-dose methyl prednisolone (HDMP) 10 mg/kg/day for 5 days i.v. (n = 10)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) 0.4 g/kg/day for 5 days (n = 10)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Conventional-dose prednisone (CDP) 2 mg/kg/day for 4 weeks p.o. (n = 10)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Vincristine 1.5 mg/m2/week i.v. 4 doses (n = 4)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: IVIG 0.4 g/kg/day for 5 days (n = 8)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Splenectomy (n = 12)
Number of subjects: 350
Study: 2825856

Group type: EXPERIMENTAL
Intervention: Acetyl‐salicylic acid as an anti‐aggregant agent
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Prophylactic central nervous system irradiation
Number of subjects: 320
Study: 31096162

Group type: EXPERIMENTAL
Intervention: ROS-responsive nanoparticles with light-triggered size-reducing, loaded with camptothecin (CPT)
Number of subjects: 0
Study: 27487492

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Gabapentin
Number of subjects: 90
Study: 26060122

Group type: EXPERIMENTAL
Intervention: 30 mg prasugrel loading dose (LD) followed by an additional 30 mg prasugrel at the time of PCI
Number of subjects: 4033

Group type: COMPARATOR
Intervention: Placebo LD followed by 60 mg prasugrel at the time of PCI
Number of subjects: 4033

Group type: EXPERIMENTAL
Intervention: Pretreatment with prasugrel LD
Number of subjects: 4033

Group type: EXPERIMENTAL
Intervention: Femoral access
Number of subjects: 4033

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 4033

Group type: EXPERIMENTAL
Intervention: Placement of >1 stent
Number of subjects: 4033

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 4033

Group type: EXPERIMENTAL
Intervention: Performed PCI
Number of subjects: 4033

Group type: EXPERIMENTAL
Intervention: Therapy with glycoprotein IIb/IIIa inhibitors
Number of subjects: 4033
Study: 23434910

Group type: EXPERIMENTAL
Intervention: Sleep following implicit training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher sleep slow-wave activity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stronger hippocampal activation at explicit knowledge retrieval
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enhanced reprocessing of hippocampal memory representations during slow-wave sleep
Number of subjects: 0
Study: 21220480

Group type: EXPERIMENTAL
Intervention: Gefitinib plus tamoxifen
Number of subjects: 290

Group type: COMPARATOR
Intervention: Placebo plus tamoxifen
Number of subjects: 290
Study: 19751326

Group type: EXPERIMENTAL
Intervention: Dental support device (DSD)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Non-device group
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 64
Study: 17181650

Group type: EXPERIMENTAL
Intervention: Everolimus 3.0 mg/day
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Everolimus 1.5 mg/day
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Everolimus 3.0 mg/day with basiliximab
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Everolimus 1.5 mg/day with basiliximab
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Everolimus (both doses)
Number of subjects: 493
Study: 15363071

Group type: EXPERIMENTAL
Intervention: Primary prevention ICD patients
Number of subjects: 978

Group type: COMPARATOR
Intervention: Secondary prevention ICD patients
Number of subjects: 978
Study: 11920260

Group type: COMPARATOR
Intervention: MP (melphalan 9 mg/m2 p.o. and prednisone 60 mg/m2 days 1-4)
Number of subjects: 914

Group type: EXPERIMENTAL
Intervention: VCMP/VBAP 'SD' (vincristine 1 mg i.v. on day 1, cyclophosphamide 500 mg/m2 i.v. on day 1, melphalan 6 mg/m2 p.o. on days 1-4, and prednisone 60 mg/m2 on days 1-4)
Number of subjects: 914

Group type: EXPERIMENTAL
Intervention: VCMP/VBAP 'HD' (increased doses of cyclophosphamide and doxorubicin)
Number of subjects: 914
Study: 9682526

Group type: EXPERIMENTAL
Intervention: Mass exposure (ME) group
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Expanding-spaced exposure (ESE) group
Number of subjects: 31
Study: 7920946

Group type: EXPERIMENTAL
Intervention: Oral estradiol valerate (E2-V) 4 mg/day for 28 days
Number of subjects: 71
Study: 2911997

Group type: EXPERIMENTAL
Intervention: Oral vitamin E supplementation (10 mg/d)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Intramuscular vitamin E supplementation (20 mg/kg/d)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (no specific control mentioned)
Number of subjects: 51
Study: 1095132

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole for two weeks
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole for six months
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (dummy tablets)
Number of subjects: 45
Study: 30732912

Group type: EXPERIMENTAL
Intervention: Exposure therapy
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control condition (lifestyle improvement)
Number of subjects: 45
Study: 31628790

Group type: EXPERIMENTAL
Intervention: Group Lifestyle Balance-Cerebrovascular Accident (GLB-CVA) intervention, a 12-month weight loss program modified for stroke patients.
Number of subjects: 64

Group type: COMPARATOR
Intervention: Waitlist control group.
Number of subjects: 64
Study: 28323947

Group type: EXPERIMENTAL
Intervention: Mixed-carotenoid supplementation (MCS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 26377389

Group type: EXPERIMENTAL
Intervention: Nasal balloon autoinflation performed three times per day for 1-3 months plus usual care
Number of subjects: 320

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 320